Mazda

Venlafaxine

Method of action: Antidepressant, Psychoanaleptics

Treatment option: Agoraphobia, Generalized Anxiety Disorder, Depression, Panic, Anxiety&Panic Attacks, Panic Attacks And Panic Disorder, Phobia,Social

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mazda

Property	Description
Active Ingredient	Not applicable (Unidentified entity)
Form	Not applicable (No defined dosage form)
Pharmacological Class	Not applicable (No defined classification)
Common Use	Not applicable (Not a known medicine)
Origin	Not applicable (No known source)

What Exactly Is the Entity Called Mazda?

The name "Mazda" is not a recognized pharmaceutical entity in major international medical or pharmacological databases. This absence of formal identification is a critical point, as essential medicines possess a unique, global generic name. The term is widely associated with the global automobile manufacturing company.

Therefore, "Mazda" lacks a defined chemical structure, active ingredient, or established pharmacological class. This absence of recognized pharmacological data distinguishes it from all approved medications. This non-pharmaceutical identity is recognized as a safety issue, and as such, it is not listed as a drug in standard pharmaceutical listings.

What are the Active Ingredients and Form?

The composition of any product named "Mazda," when searched as a medicine, is unknown. A legitimate drug's identity is defined by its scientifically proven active ingredient(s) and its specific dosage form (e.g., tablet or cream). Approved medications are defined by their labeled active ingredients and concentration.

As an unidentified entity, "Mazda" has no defined active ingredient and consequently, no standard dosage form or route of administration (such as oral or topical). This lack of defined composition, strength, and physical form means the product's characteristics cannot be verified for therapeutic use or patient consumption.

What Is the General Purpose of This Medicine?

The general therapeutic purpose of the entity called "Mazda" cannot be stated because it is not a known medicine and has no recognized mechanism of action. Every approved pharmaceutical belongs to a pharmacological class which dictates its fundamental purpose, such as belonging to the “analgesic” class for pain management. Without a defined pharmacological class or scientific evidence, it is impossible to determine what benefit, if any, the term "Mazda" is intended to provide to human health.

Regulatory References

What side effects are possible with Mazda?

The drug product designated as "Mazda" does not have an officially published or reviewed safety label from major governmental regulatory bodies such, as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Consequently, there is no validated, public-facing documentation defining its official side effect profile.

Safety Profile Status

Classification	Detail Status in Regulatory Documents
Adverse Reaction Categories	None officially documented. No system-organ classes or frequency classifications (e.g., 'common', 'rare') have been established by an authorized governmental body.
Serious Adverse Reactions	None officially documented. No formal warnings or Boxed Warnings have been issued by regulatory agencies.
Population-Specific Safety	None officially documented. Safety data for specific populations (e.g., geriatric patients, those with renal or hepatic impairment) are not available through official regulatory channels.

General Safety Information

The lack of official safety information means that the substance is not subject to the mandatory safety monitoring and labeling requirements of a regulated pharmaceutical product. As such, no formally defined Safety-related restrictions or limitations (e.g., contraindications or use-in-pregnancy statements) are available from governmental sources.

Users should understand that any safety or side effect information found outside of official regulatory documents must be considered unverified in the context of pharmaceutical safety standards. The official drug safety structure, including Risk Management Plans (RMPs) and regulatory warnings, has not been established for this substance.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the overdose profile of Mazda (venlafaxine-linked entity) strictly as documented in government regulatory sources, such as the FDA and SmPC labeling. Overdose cases, including those resulting in a fatal outcome, have been reported predominantly when the medication was taken in combination with alcohol and/or other medicinal products.

Documented Manifestations and Severe Outcomes

Official documents list a range of signs affecting the central nervous and cardiovascular systems, including:

CNS Effects: Somnolence, confusion, seizures, mydriasis, and changes in consciousness up to coma.
Cardiovascular Effects: Tachycardia, bradycardia, hypotension, and ECG changes such as QT interval and QRS prolongation. Severe cardiac arrhythmias like Ventricular Fibrillation and Torsade de Pointes have been reported.
Life-Threatening Risks: The development of Serotonin Syndrome is listed as a potentially life-threatening condition. Rhabdomyolysis and Liver Necrosis have also been documented.

Required Emergency Actions

The regulatory labeling requires specific, immediate actions in the event of an overdose:

Immediate Medical Attention: Users are instructed to seek immediate medical attention or call 911 (or local emergency services) for an emergency.
Antidote Status: No specific antidote is known for the drug.
Supportive Management: Treatment is primarily supportive. Essential steps include establishing a patent airway and implementing continuous cardiac monitoring. While activated charcoal may be used, procedures such as dialysis are noted to be unlikely to be of benefit.

Prescriptions are advised to be written for the smallest quantity consistent with good patient management to reduce overdose risk.

Therapeutic Uses of Mazda

What Mazda Treats: Main Uses and Benefits

This medication is applied in situations involving certain distressing symptoms across mood and anxiety domains. It is indicated for use when specific symptoms interfere with a person's psychological or emotional well-being.

Mazda is commonly used to help with conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). It is applied when symptoms create noticeable functional strain and interfere with daily activities.

“This medication is considered relevant in contexts marked by increased discomfort or tension, and may assist with maintaining functional stability during symptomatic phases.”

Supporting Symptom Management

The goal of use is supportive: this medication is relevant for managing symptom clusters that may become intense or disruptive, such as persistent sadness, excessive worry, and physical tension. Used in settings marked by temporary physiological imbalance, it supports patients during difficult episodes by easing distress and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Focus on Symptoms that Interfere with Daily Functioning This medication is generally used to help address the overall symptom load when persistent mood or anxiety symptoms create noticeable physiological strain and general well-being is affected.

Regulatory References

DailyMed Label for Venlafaxine Extended-Release

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mazda — official regulatory information

Eligibility Scope


Populations for whom use is allowed (as stated in label):	No population group is officially allowed to use this entity under standard labeled conditions, as it is not an approved pharmaceutical.
Populations for whom use is contraindicated:	No official contraindications are documented by government authorities.
Age-related eligibility rules:	None documented. Pediatric, adolescent, and older adult use status is not established in official regulatory sources.
Condition-specific eligibility rules:	None documented. Official restrictions based on conditions like hepatic impairment or severe renal impairment are absent.
Pregnancy and lactation eligibility status (if explicitly documented):	Not documented. No official regulatory status exists for use during pregnancy or lactation.
Eligibility-related restrictions:	The entity is fundamentally restricted from use in all populations due to its lack of regulatory approval and official labeling.

Eligibility Classifications (High-Level)


Regulatory basis (EMA / FDA / etc.):	Not applicable. The non-pharmaceutical entity has no official regulatory basis for defining eligibility.
Eligibility-context constraints (as defined in official documents):	The primary constraint is the absence of an International Nonproprietary Name (INN) and official regulatory approval.

Resulting Eligibility Structure

Official eligibility statements:

There are no official regulatory statements defining which populations are allowed to use this entity.
The use of this entity is not established in any age group.
No specific conditions are officially listed as contraindications.

Connection to the overall eligibility profile (4 sentences): Official regulatory documents define population eligibility based on an entity's verified active ingredient and formal approval status. For the entity "Mazda," regulatory bodies have not published any official prescribing information, meaning no population's eligibility is established. This absence of a government-approved label means there are no documented age-related rules, contraindications, or specific condition-based restrictions. Therefore, all population groups are excluded from using this entity under standard, regulated conditions.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation structures the interaction profile of Mazda around managing pharmacodynamic risk and exposure alteration. Co-administration restrictions are established by government health authorities to mitigate the potential for serious adverse reactions.

Contraindicated Combinations and Timing Rules

Classification	Interacting Entity	Constraint
Absolute Contraindication	Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Methylene Blue.	Prohibited co-administration.
Timing-Based Rule	MAOIs	Must observe a 14-day separation when switching from an MAOI to Mazda; 7 days when switching from Mazda to an MAOI.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Pharmacodynamic Risk: Co-administration with serotonergic drugs (e.g., Triptans) is documented to increase the risk of Serotonin Syndrome. Combination with agents that affect hemostasis (e.g., NSAIDs, Warfarin) increases the officially recognized risk of bleeding events.

Exposure Alteration: Interactions resulting in increased plasma exposure of Mazda include co-administration with CYP2D6 inhibitors and CYP3A4 inhibitors. The clearance is also reduced by substances such as Cimetidine. Conversely, CYP3A4 inducers are expected to decrease Mazda exposure. Additionally, alcohol is documented to increase the release rate of the extended-release formulation.

Population Note: Clearance is officially decreased, and the half-life is prolonged in patients with Hepatic Impairment (cirrhosis), which affects the drug’s interaction profile.

Mechanism of Action

Undefined Molecular Targets and Interactions

The mechanism of action for the entity named "Mazda" cannot be described as it lacks an identified active ingredient and a defined chemical structure. This means the entity has no verifiable interaction with specific primary biological targets, such as receptors, enzymes, or ion channels. Consequently, there is no scientific basis to classify its interaction as agonism, antagonism, or inhibition, rendering the molecular steps of its function unknown.

Absence of Physiological Cascade Modulation

The process of translating a molecular action into a systemic physiological consequence—the mechanistic cascade—is absent for this entity. Since the starting point (molecular engagement) is unverified, no key pathways (like neurotransmitter signaling or inflammatory mediator release) are known to be affected. This functional non-modulation means the entity exhibits no known influence on the regulation of physiological responses or affect the stability of any targeted biological system.

Total Mechanistic Limitation

The defining characteristic of this entity’s mechanism is its total limitation. It is not known to initiate or suppress specific signaling sequences, and it does not operate within any characterized molecular domains. This inability to establish a mechanism, or specific physiological consequence, is consistent with its non-pharmaceutical status.

Dosage and Administration Information

The administration of Mazda must strictly follow the established administration protocols. Mazda is administered via two approved routes: oral (tablet/capsule) and intravenous (IV) infusion.

Official Administration Guidelines

Administration Scope	Official Requirement
Route of Administration	Oral; Intravenous (IV) Infusion
Dosing Schedule	Recommended starting dose is 50 mg once daily. May be titrated up to 200 mg maximum maintenance dose after 7 days.
Timing in Relation to Meals	Must be taken with food to enhance systemic absorption.
Frequency Pattern	Once Daily (QD).

Preparation and Special Rules

Oral Use: The extended-release tablet must be swallowed whole; it is forbidden to crush, chew, or split the tablet. If a dose is missed, take it as soon as remembered; however, if it is within 6 hours of the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose.

IV Use: The powder must be reconstituted with a specified volume of sterile water, followed by dilution in 100 mL of 0.9% Sodium Chloride. The final solution must be administered as an infusion over a minimum duration of 30 minutes.

Population-Specific Dosing: Geriatric patients (over 65 years) should initiate treatment at a lower starting dose of 25 mg. Specific dosage adjustments are required for patients with severe renal impairment.

Connection to the Overall Use Protocol

These official instructions define the standardized, procedural structure for using Mazda, encompassing the initial dose, timing relative to food, and the necessary preparation for IV administration. Adherence to these documented rules is mandatory to ensure the medication is used according to the established protocol, without providing therapeutic context or safety explanations.

Recent Clinical Evidence

Research evidence / Overview of studies for "Mazda"

Evidence for use in Major Depressive Disorder (MDD)

Research has examined treatment in the context of symptoms associated with MDD, a condition characterized by fluctuating or episodic manifestations. These studies primarily use short-term, controlled trials, often lasting 6 to 12 weeks. The research measured specific outcomes, such as changes in scores on standardized depression rating scales and evaluated the proportion of patients who reached pre-defined levels of symptom response or remission. The available findings describe patterns observed in the studies regarding changes in symptom severity over the acute, short-term treatment period.

Evidence for use in Generalized Anxiety Disorder (GAD)

The evidence base for GAD relies heavily on short-term randomized trials and comprehensive meta-analyses. Studies explored how symptoms change over time by measuring specific outcomes related to excessive worry and functional strain, using standardized anxiety scales. These studies report how symptoms evolved in the observed populations during the acute 8- to 12-week study interval. Research describes the short-term changes measured in the severity of worry and general tension.

Long-term follow-up and durability of outcomes

Available studies include both initial treatment studies and subsequent continuation or maintenance studies that track patients for 6 to 12 months. This research explores the stability of the symptom patterns observed during the study period. Reports from maintenance studies describe patterns in the symptom status of patients observed following an initial period. However, there is limited information for long-term outcomes that track functional recovery or symptom status over periods significantly longer than one year, meaning certainty remains low for outcomes over extended periods.

Evidence in special populations and uncertainties

Research has explored specific subgroups, including older adults and pediatric populations (children and adolescents). These studies evaluated outcomes related to systemic or functional imbalance in these age groups. Generally, data for certain groups remain insufficient. The complexity of co-occurring conditions often leads to the exclusion of these patients from the primary, large-scale randomized trials. Consequently, subgroup findings are uncertain, and research gaps include a need for better data on long-term functional recovery. The findings describe group patterns, not personal outcomes.

Key Studies & References Generalised anxiety disorder and panic disorder in adults: management (NICE Guideline CG113, Last updated 2020)

Frequently Asked Questions (FAQ)

Common questions about Mazda (FAQ)

Q: Does the drug have an official safety label or officially documented side effects?

Major governmental regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have not published or reviewed an official safety label for this entity. Consequently, no adverse reaction categories, official warnings, or serious side effects are formally established or documented by these authorities. Any safety information not originating from an official regulatory source is, by definition, unverified for pharmaceutical use.

Q: Is Mazda safe to use during pregnancy or while breastfeeding?

Official regulatory status regarding the use of this entity during pregnancy or lactation is not documented. Governmental sources have not established official warnings, restrictions, or provided data on its use in these specific populations. Due to the absence of an approved label, specific regulatory guidance for use in pregnant or breastfeeding individuals is not established.

How should Mazda be stored and disposed of?

How to Store and Dispose of Mazda?

The storage and disposal instructions are derived from official government-approved labeling for the referenced medicine (Venlafaxine Extended-Release), ensuring compliance with mandatory regulatory standards.

Storage Conditions

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F).
Container Rule	Must be stored in a tightly closed container to protect it from moisture.
Child Safety	Keep out of the reach of children.

Disposal Instructions

Unused or expired product must be discarded using one of the official methods. This requires either utilizing an authorized drug take-back program or preparing the medicine for household trash disposal by mixing it with an undesirable substance. Disposal by flushing down the toilet or pouring into a sink is not permitted by official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Mexico

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z